Institute for Implementation Science in Population Health, City University of New York. New York, NY.
CityMD/Summit Medical Group, New York, NY.
Ann Epidemiol. 2022 Oct;74:31-40. doi: 10.1016/j.annepidem.2022.05.006. Epub 2022 Jun 2.
Tracking severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing and positivity trends is crucial for understanding the trajectory of the pandemic. We describe demographic and clinical characteristics, testing, and positivity rates for SARS-CoV-2 among 2.8 million patients evaluated at an urgent care provider.
We conducted a retrospective study of patients receiving a diagnostic or serologic test for SARS-CoV-2 between March 1, 2020 and July 20, 2021 at 115 CityMD locations in the New York metropolitan area. Temporal trends in SARS-CoV-2 positivity by diagnostic and serologic tests stratified by age, sex, race/ethnicity, and borough of residence were assessed.
During the study period, 6.1 million COVID diagnostic and serological tests were performed on 2.8 million individuals. Testing levels were higher among 20-29-year-old, non-Hispanic White, and female patients compared with other groups. About 35% were repeat testers. Reverse transcriptase polymerase chain reaction positivity was higher in non-Hispanic Black (7.9%), Hispanic (8.2%), and Native American (8.2%) compared to non-Hispanic White (5.7%) patients. Overall seropositivity was estimated to be 22.1% (95% confidence interval: 22.0-22.2) and was highest among 10-14 year olds (27.9%), and non-Hispanic Black (26.0%) and Hispanic (31.0%) testers.
Urgent care centers can provide broad access to diagnostic testing and critical evaluation for ambulatory patients during pandemics, especially in population-dense, urban epicenters. Urgent care center electronic medical records data can provide in-depth surveillance during pandemics complementary to citywide health department data sources.
跟踪严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)检测和阳性趋势对于了解大流行轨迹至关重要。我们描述了在纽约都会区 115 个 CityMD 地点接受 SARS-CoV-2 诊断或血清学检测的 280 万患者的人口统计学和临床特征、检测和阳性率。
我们对 2020 年 3 月 1 日至 2021 年 7 月 20 日期间在纽约都会区 115 个 CityMD 地点接受 SARS-CoV-2 诊断或血清学检测的 280 万患者进行了回顾性研究。按年龄、性别、种族/族裔和居住行政区对诊断和血清学检测的 SARS-CoV-2 阳性率的时间趋势进行了评估。
在研究期间,对 280 万人进行了 610 万次 COVID 诊断和血清学检测。与其他组相比,20-29 岁、非西班牙裔白人和女性患者的检测水平较高。约 35%为重复检测者。与非西班牙裔白人(5.7%)患者相比,非西班牙裔黑人(7.9%)、西班牙裔(8.2%)和美国原住民(8.2%)患者的逆转录酶聚合酶链反应阳性率更高。总体血清阳性率估计为 22.1%(95%置信区间:22.0-22.2),10-14 岁组最高(27.9%),非西班牙裔黑人(26.0%)和西班牙裔(31.0%)检测者最高。
在大流行期间,急诊中心可为门诊患者提供广泛的诊断检测和关键评估,尤其是在人口密集、城市中心地带。急诊中心电子病历数据可在大流行期间提供与全市卫生部门数据源互补的深入监测。